Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Sponsor: NSABP Foundation Inc
Listed as NCT01547741, this PHASE3 trial focuses on Breast Cancer and remains ongoing. Sponsored by NSABP Foundation Inc, it has been updated 10 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
May 2024 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
May 2022 — May 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — May 2022 [monthly]
Active Not Recruiting PHASE3
-
Feb 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Apr 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NSABP Foundation Inc
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .